Editorial comment.
de la Rosette
Jean J M C H
JJ
D002243:Carbolines / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D007172:Erectile Dysfunction / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D053448:Prostatism / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011788:Quality of Life; D018570:Risk Assessment; D000068581:Tadalafil; D016896:Treatment Outcome; D014555:Urination Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil